Bristol-Myers Squibb Company
General ticker "BMY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $110.9B (TTM average)
Bristol-Myers Squibb Company follows the US Stock Market performance with the rate: 34.0%.
Estimated limits based on current volatility of 2.4%: low 58.34$, high 61.17$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 bmo
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-10-02, amount 0.63$ (Y4.22%)
- Total employees count: 32500 (-4.7%) as of 2025
- US accounted for 69.1% of revenue in the fiscal year ended 2025-12-31
- Top business risk factors: Pricing pressure, R&D failure, Regulatory and compliance, Market competition, Loss of primary products
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [42.51$, 64.47$]
- 2026-12-31 to 2027-12-31 estimated range: [45.08$, 68.06$]
Financial Metrics affecting the BMY estimates:
- Positive: with PPE of 8.8 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 19.63
- Positive: 11.37 < Operating cash flow per share per price, % of 12.76
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: Interest expense per share per price, % of 1.70 <= 2.54
- Positive: -4.49 < Investing cash flow per share per price, % of -3.72
- Negative: 0 < Inventory ratio change, % of 0.24
- Positive: 7.19 < Return on assets ratio (scaled to [-100,100]) of 7.27
Short-term BMY quotes
Relationship graph
Long-term BMY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $45,006.00MM | $47,407.00MM | $47,520.00MM |
| Operating Expenses | $36,534.00MM | $55,786.00MM | $38,192.00MM |
| Operating Income | $8,472.00MM | $-8,379.00MM | $9,328.00MM |
| Non-Operating Income | $-32.00MM | $0.00MM | $0.00MM |
| Interest Expense | $1,166.00MM | $1,947.00MM | $1,891.00MM |
| R&D Expense | $9,299.00MM | $11,159.00MM | $9,951.00MM |
| Income(Loss) | $8,440.00MM | $-8,379.00MM | $9,328.00MM |
| Taxes | $400.00MM | $554.00MM | $2,272.00MM |
| Net Income(Loss)* | $8,025.00MM | $-8,948.00MM | $7,054.00MM |
| Stockholders Equity | $29,430.00MM | $16,335.00MM | $18,473.00MM |
| Inventory | $2,662.00MM | $2,557.00MM | $2,690.00MM |
| Assets | $95,159.00MM | $92,603.00MM | $90,038.00MM |
| Operating Cash Flow | $13,860.00MM | $15,190.00MM | $14,156.00MM |
| Capital expenditure | $1,209.00MM | $1,248.00MM | $1,311.00MM |
| Investing Cash Flow | $-2,295.00MM | $-21,352.00MM | $-4,132.00MM |
| Financing Cash Flow | $-9,416.00MM | $5,127.00MM | $-10,348.00MM |
| Earnings Per Share** | $3.88 | $-4.41 | $3.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.